Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

U.S. FDA Fast Track designation granted to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for the treatment of patients ...
Targeted Oncology

FDA Grants Fast Track Designation to FRα-Targeting ADC for Ovarian Cancer

The FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for ...

Zymeworks Gets FDA Fast-Track Designation for ZW191 in Ovarian Cancer

Zymeworks has won the Food and Drug Administration's fast-track designation for its ZW191 antibody-drug conjugate for patients with advanced or metastatic platinum-resistant ovarian cancer.
CURE

FDA Fast Tracks ZW191 for Platinum-Resistant Ovarian Cancer

FDA fast tracked ZW191 for platinum-resistant ovarian cancer, aiming to speed development of a potential new option for patients with limited treatments. The U.S. Food and Drug Administration (FDA) ...
Renal & Urology News

FDA Provides Fast Track Designation to Nipocalimab for Systemic Lupus Erythematosus

Nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE). Fast Track designation is designed to ...
Healio

FDA grants fast track designation to nipocalimab for adults with lupus

The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus ...
Yahoo

Affinia receives FDA fast track designation for AFTX-201

Add Yahoo as a preferred source to see more of our stories on Google. The therapy is being evaluated in the ongoing Phase I/II UPBEAT clinical trial in BAG3 DCM patients. Credit: NMK-Studio / ...